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Abstract
Background: Using text messaging for vaccine safety monitoring, particularly for non-medically 
attended events, would be valuable for pandemic influenza and emergency vaccination program 
preparedness. We assessed the feasibility and acceptability of text messaging to evaluate fever and 
wheezing post-influenza vaccination in a prospective, observational, multi-site pediatric study.
Methods: Children aged 2–11 years old, with an emphasis on children with asthma, were 
recruited during the 2014–2015 influenza season from three community-based clinics in New York 
City, and during the 2014–2015 and 2015–2016 seasons from a private practice in Fall River, 
Massachusetts. Parents of enrolled children receiving quadrivalent live attenuated (LAIV4) or 
inactivated influenza vaccine (IIV4) replied to text messages assessing respiratory symptoms (day 
3 and 7, then weekly through day 42), and temperature on the night of vaccination and the next 
seven nights (day 0–7). Missing data were collected via diary (day 0–7 only) and phone. Phone 
confirmation was obtained for both presence and absence of respiratory symptoms. Reporting 
rates, fever (T ≥ 100.4 °F) frequency, proportion of wheezing and/or chest tightness reports 
captured via text message versus all sources (text, phone, diary, electronic health record) and 
parental satisfaction were assessed.
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Results: Across both seasons, 266 children were analyzed; 49.2% with asthma. Parental text 
message response rates were high (>70%) across sites. Overall, fever frequency was low (day 0–2: 
4.1% [95% confidence interval (CI) 2.3–7.4%]; d3–7: 6.7% [95% CI 4.1–10.8%]). A third 
(39.2%) of parents reported a respiratory problem in their child, primarily cough. Most (88.2%) of 
the 52 wheezing and/or chest tightness reports were by text message. Most (88.1%) participants 
preferred text messaging over paper reporting.
Conclusions: Text messaging can provide information about pediatric post-vaccination fever 
and wheezing and was viewed positively by parents. It could be a helpful tool for rapid vaccine 
safety monitoring during a pandemic or other emergency vaccination program.
Conclusions: Trial registration: clinicaltrials.gov Identifier: .
Keywords
Influenza; Wheeze; Asthma; Vaccination; Influenza vaccination; Vaccine safety; Text message; 
SMS
1. Introduction
The Advisory Committee on Immunization Practices (ACIP) recommends influenza 
vaccination for all individuals ≥6 months-old [1]. Understanding influenza vaccine safety is 
important for annual vaccination programs and pandemic preparedness. Influenza vaccine is 
the only vaccine recommended annually, with formulations often changing yearly [2]. While 
seasonal vaccine safety patterns are usually similar, unexpected adverse events may arise. 
For example, the 2010–2011 trivalent inactivated influenza vaccine was associated with an 
increased febrile seizure risk in young children [3].
Although following a large number of vaccinated people prospectively for post-licensure 
vaccine-associated adverse events can be labor-intensive and expensive, we and others have 
successfully used text messaging- a scalable, low-cost method- for this purpose [4–8]. 
Currently, 95% of American adults have a cell phone [9]. Cell phone use is thought to be 
higher in harder-to-reach low-income populations [10] that may not be included in vaccine 
safety monitoring programs relying on information from managed care organizations [11]. 
Text messaging is particularly useful for monitoring of non-medically attended events, such 
as fever, since it allows patients or caregivers to report symptoms directly. This may be 
important in an influenza pandemic when information may need to be gathered rapidly and 
simultaneously from large numbers of vaccinated people nationally, but visits to medical 
facilities may be limited. Some important issues remain in the use of text messaging for 
monitoring vaccine-associated adverse events. First, adverse events may occur several weeks 
post-vaccination, but previous pediatric studies have focused primarily on the more 
immediate 7–10 days post-vaccination. Second, unlike in Australia [12], text messaging has 
not been used to date in the United States to assess vaccine safety outcomes at multiple sites, 
but multi-site vaccine safety monitoring would have value for pandemic and emergency 
vaccination program preparedness. Third, although wheezing is not considered a safety 
concern after IIV, accuracy of text messaging to capture respiratory events may be pertinent 
for monitoring safety of live attenuated influenza vaccination (LAIV) [13]. During our study 
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period, ACIP recommended LAIV preferentially for healthy 2- through 8-year olds for the 
2014–15 season; for 2015–16 season there was no preferential recommendation, but LAIV 
was an acceptable option for use in healthy children [14,15].
This study’s primary goal was to assess feasibility and acceptability of text messaging to 
assess wheezing prospectively from day 0 (vaccination day) through day 42 post-vaccination 
in children aged 2–11 years-old receiving quadrivalent live attenuated (LAIV4) or 
inactivated (IIV4) influenza vaccine. We hypothesized that (1) at least 80% of wheezing 
symptoms reported via text message would be verified by phone interview, in those able to 
be reached, and medical record review for those with a visit; (2) response rates to text 
message queries regarding wheezing symptoms would be higher on days 3 and 7 post-
vaccination than on days 14–42; and (3) at least 80% of parents would have a high level of 
satisfaction with using text messaging to report wheezing occurring post-vaccination. A 
secondary objective was to assess feasibility of monitoring post-vaccination wheezing and 
fever using text messaging at multiple sites. We hypothesized that text message response 
rates would not differ by more than 10 percentage points between sites.
2. Materials and methods
This prospective observational study was conducted during the 2014–2015 (Year 1) and 
2015–2016 (Year 2) influenza seasons, in collaboration with the Centers for Disease Control 
and Prevention (CDC). During the 2014–2015 season, children were recruited from three 
community-based clinics affiliated with New York-Presbyterian Hospital/Columbia 
University Medical Center (CUMC) in New York City. These sites serve a primarily Latino, 
publicly-insured population and share an electronic health record (EHR) system with the 
hospital. During the 2014–2015 and 2015–2016 seasons, children were recruited from a 
private general pediatric practice in Fall River, Massachusetts affiliated with Boston Medical 
Center (BMC) that has its own EHR system. Each child also had a parent or guardian 
participate in the study. All text messages for both sites were sent from a centralized 
program to the parent (or guardian) participating in the study. Vaccination decisions were 
made by the patients’ health care provider and caregivers, and all influenza vaccines 
administered were the quadrivalent forms. The influenza vaccine strain composition differed 
in the two seasons for both an A and B strain. CUMC and BMC’s Institutional Review 
Boards (IRB) approved the study; CDC relied on the CUMC approval.
Children were eligible for enrollment if they (1) were 2–11 years-old, (2) were receiving 
their first or second influenza dose of that season, (3) their parent had a cell phone with text 
messaging capabilities, and (4) their parent spoke English or Spanish at CUMC sites or 
English at the BMC site. Exclusion criteria included (1) any chronic medical condition 
considered a contraindication or precaution for LAIV (with the exception of asthma/
wheezing history) [14], (2) current/recent (<2 weeks) asthma exacerbation, (3) oral or other 
systemic steroid use in the preceding 2 weeks, (4) temperature (T) ≥100.4 °F at vaccination, 
(5) antipyretic administration within 6-hours pre-vaccination or stated intent to use 
prophylactic antipyretics, (6) parental inability to read or send text messages, and (7) sibling 
or child already enrolled in either season. Receipt of other vaccines was not an exclusion 
criterion.
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2.1. Study procedures
Parents provided consent and completed an intake form, including demographic information 
and parent-reported child history of asthma/reactive airway disease (RAD)/recurrent 
wheezing. Study staff reviewed text message procedures. Parents received and were trained 
with a temporal artery thermometer [16], and were given a paper diary in a pre-addressed/
pre-stamped envelope to return after the first 7-day observation period.
Parents were asked to take their child’s temperature each evening from the day of 
vaccination (day 0) through the next 7 days, or at any time during those days if the child felt 
febrile. Parents were sent an interactive text message (in English or Spanish, based on 
participant language choice) nightly, asking the highest temperature, time taken, name and 
time of any antipyretics given, and care sought. Respiratory questions were sent on days 3, 
7, 14, 21, 28, 35 and 42 (none, wheeze, cough, and/or chest tightness). 1f respiratory 
symptoms were reported, additional information was prompted including medications and 
care visits. Unanswered text messages were re-sent 20 minutes later to prompt a response.
The centralized text messaging program had built-in messages sent back for an unexpected 
reply (e.g. T < 95 °F or >106 °F degrees) with instructions to correct the error. Study staff 
reviewed messages daily initiating contact with non-responders to collect missing data, and 
with responders reporting respiratory symptoms to confirm them. Parents that reported either 
no respiratory symptoms on d3–d21 texts or no symptoms some days and failed to report 
other days, were called soon after d21 to confirm the child had no symptoms. A telephone 
exit survey was administered to all participants after the last text message was sent on d42 to 
confirm absence or presence of respiratory symptoms occurring on d28–d42 and assess 
parental satisfaction.
Vaccinations given at enrollment and during d1–d42 post-vaccination, as well as all 
healthcare visits (ambulatory care, emergency department and hospital) between d0–d42 
post-vaccination, were abstracted from the EHR. Chart documentation of history of 
asthma/RAD/recurrent wheezing, as well as associated medications, were abstracted. 
Abstracted data were used by two separate investigators per site to adjudicate whether the 
child had chart documentation of asthma exacerbation and/or asthma medication 
prescription documented within 12 months before enrollment (i.e., recent history), or 
asthma/RAD/ recurrent wheezing diagnosis not meeting criteria as above (i.e., remote 
history), or no history of asthma exacerbation or medication prescription. Adjudication 
discrepancies were reviewed and a final decision made by the entire research team.
2.2. Data analysis
Response rates to d3 and d7 text messages were compared to response rates sent weekly 
from days 14–42 using a paired t-test. A scale from 0 to 1 was calculated in which 0 was 
responding no days, 1 was defined as responding all days, and numbers between 0 and 1 
represented the ratio of number of days responded per number of days messages were sent. 
This was then multiplied by 100 to result in a percent.
We described fever reported via text (any: T ≥ 100.4 °F; moderate to severe: T ≥ 102.2 °F) 
for d0–2 and d3–7 separately. These analyses included participants who reported on all days 
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of the reporting period (d0–2, d3–7 separately) as well any child with fever even if the 
parent did not report all days in period. The d0–2 window was selected based on the 
increased fever risk previously observed on day 2 post-LAIV vaccination [17], and the 
known day 0–1 fever risk window after IIV [18].
To assess accuracy, we noted how many reports of wheezing and/or chest tightness were 
reported by any source (text, phone, diary [diary available for days 3 and 7 only], or EHR). 
We calculated the proportion of episodes captured via text message. For those who texted 
and we were able to reach by phone, we categorized each report via text message as 
concordant or discordant (texted respiratory symptom confirmed or not by phone). Results 
were tabulated separately for cough. We also describe the proportion of those with wheezing 
and/or chest tightness overall, by vaccine type and by history of asthma/RAD/recurrent 
wheezing.
A convenience sample size for this feasibility study was set to be at least 150 children and 
their caregivers in year 1 and 100 in year 2. Although asthma/RAD/recurrent wheezing was 
not an eligibility criterion, the goal was to enroll approximately 70% of children with this 
history in order to increase the chances for respiratory events.
3. Results
Two-hundred and sixty-eight children and their parent/guardian were enrolled: 168 in 2014–
2015 and 100 in 2015–2016. Two participants were excluded from analysis (Fig. 1). Most 
children (72.9%) received IIV4 (Table 1). Demographic characteristics differed by 
recruitment site (Supplemental Table 1). The proportion of children with parent-reported 
history of asthma/RAD/recurrent wheezing was 32.5% in 2014–2015 (enrollment began in 
December) and 69.0% in 2015–2016 (enrollment began in October).
Chart adjudication identified 131 (49.2%) children with a history of asthma/RAD/recurrent 
wheezing. Nearly all children with an asthma history received IIV4. Most (105/112; 93.8%) 
children with a chart-adjudicated history of asthma/RAD/recurrent wheezing in the last 12 
months also had parent-reported asthma medication use in the last 12 months. Most 
(105/111; 94.6%) children with parent-reported asthma medication use in the last 12 months 
also had a recent chart history, and the remaining had a remote chart history.
Three (1.1%) participants requested to stop messages and two (0.8%) lost text message or 
phone service during the 42 days observation period. Half (53.0%) returned the diary in Year 
1 and 78.0% in Year 2. Individual text message response rates were above 70% on all days 
across all sites (Fig. 2) though rates varied by day. Mean response rate for those who had 
text messages delivered was 88% ± 25% overall and was similar between the study period 
d3–7 versus d14–42 (90% ± 25% vs. 88% ± 27%; p = .26). Mean response rate was 
significantly higher at the BMC-affiliated site (95% ± 15% vs. 79% ± 32%; p <.001). Due to 
demographic differences by sites, results were stratified. When stratified by site, there were 
no differences in response rates by age, gender, preferred language, education level, text 
message plan or utilization of the respondent, or age, sex, race, ethnicity, insurance status of 
the child. In addition, across both sites combined, all demographic sub-groups had response 
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rates of ≥80% with the exception of those who did not have unlimited texting (76% ± 36%) 
or did not text daily at baseline (74% ± 31%).
3.1. Fever and respiratory symptoms
The majority of fever and respiratory symptom data were collected via text message at both 
sites (Fig. 3). Fever frequency was low and similar between IIV4 and LAIV4 groups. Day 0–
2 fever for both years combined was 4.1% (95% CI 2.3–7.4%) (LAIV4 2.9% [95% CI 0.8–
10.1%]; IIV4 4.6% [95% CI 2.3–8.8%]). Fever frequency from d3–7 was also low: 6.7% 
(95% CI 4.1–10.8%) (LAIV4 3.6% [95% CI 1.0–12.1%]; IIV4 7.7% [95% CI 4.6–12.8%]). 
There was no statistically significant difference in day 0–2 fever among those with (1.7%) 
and without other vaccines (4.9%) administered at enrollment (p = .27), but there was a 
statistically significant difference for day 3–7 fever (16.7% with vs. 3.5% without other 
vaccines, p = .001). Of the 9 children with d3–7 fever who also received another vaccine, 
one received LAIV4 with other vaccines (Measles/Mumps/Rubella (MMR)-Varicella, 
Diphtheria/Tetanus/acellular Pertussis (DTaP)-inactivated polio vaccine (IPV), Hepatitis B, 
Hepatitis A) and eight received IIV4 with other vaccines ([MMR-Varicella (n = 2); DTaP-
IPV (n = 2); Varicella, DTaP-IPV (n = 1); Hepatitis A (n = 1); Tdap, MenACWY-CRM (n = 
1) and Hepatitis A, Haemophilus influenzae type b (n = 1)].
Overall, 39.2% of parents (37.2% at CUMC and 40.7% at BMC) who responded to at least 
one respiratory text message reported a problem (primarily cough). A total of 52 episodes of 
wheezing and/or chest tightness were reported during the study period; 27 episodes in Year 1 
and 25 in Year 2. The highest frequencies of episodes were on day 7 (3.5%) and day 14 
(3.9%).
Most episodes were reported via text message (88.5% overall, 89.5% CUMC and 87.9% 
BMC). Of the 35 episodes reported via text message for which we were able to reach the 
parent for confirmation, all but one were confirmed (97.1%).
Overall, 13.7% of children (95% CI 10.1–18.4%) had at least one episode of wheezing 
and/or chest tightness. Proportions were higher for IIV4 but not significantly (LAIV4 7.1% 
[95% CI 3.1–15.7%]; IIV4 16.1% [95% CI 11.6–22.0%](p = .061). A higher proportion of 
children with a recent history of asthma/wheezing/RAD on chart adjudication had wheezing 
and/or chest tightness [24.3% (95% CI 17.3–33.0%)] versus those who had a remote history 
[5.3% (95% CI 0.9–24.6%)]. Proportions were similar by vaccine type in those with a recent 
history (LAIV4 25.0% [95% CI 4.6–69.9%]; IIV4 24.3% [95% CI 17.2–33.2%]). Only 4 of 
these children received LAIV4. There was no difference in proportion of children with 
wheezing/chest tightness among those who did (9.4%) or did not (15.2%) have other 
vaccines administered at enrollment (p = .24).
There were 103 episodes of cough reported in Year 1 and 83 in Year 2 by text message, 
phone and/or diary. Most (86.6%) were reported via text message. Of the 141 episodes 
reported via text message for whom we were able to reach the parent for confirmation, all 
were confirmed.
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Few episodes of wheeze and/or chest tightness resulted in medical visits (3 of 27, 11.1% in 
Year 1; 6 of 25, 24.0% in Year 2). Similarly, few episodes of cough alone resulted in medical 
visits (8 of 86, 9.3%) in Year 1; 7 of 71, 9.9% in Year 2). In Year 1 and 2 combined, 56 
participants had at least one medical visit for any reason in the 42 days post-vaccination (13 
emergency department, 45 primary care, 7 specialty care, 1 elective hospitalization).
3.2. Parental survey
Most parents completed the exit survey (83.6% CUMC, 94.7% BMC). Nearly all (99.6%) 
surveyed were satisfied taking part in the study (76.9% very satisfied, 22.7% satisfied) and 
would be very likely to recommend it to other families (87.4%). Most (96.6%) would be 
willing to take part in a future study using text messaging to follow their child’s health 
(79.8% very willing, 16.8% somewhat willing). Most (88.1%) preferred text messaging over 
paper reporting. Nearly 1 in 5 (19.2%) parents reported that taking part in the study 
positively affected their views on vaccine safety, and only 0.8% reported a potentially 
negative effect.
4. Discussion
We demonstrated in this novel study that text messaging is a reliable method to identify 
post-vaccination respiratory symptoms both in the more immediate seven days post-
vaccination as well as through 42 days post-vaccination with most episodes- both medically 
attended and non-medically attended- being captured by text message. It also showed 
acceptability with high response rates and parental satisfaction. Finally, it was a successful 
demonstration of a central text messaging program with inclusion of a geographically distant 
health facility with no previous experience with text message monitoring. Response rates 
were high across sub-populations, which may be important for planning future pandemic or 
emergency vaccination safety programs.
Wheezing is considered to be an important outcome of interest in vaccine safety assessments 
[19], and there was a specific concern about wheezing after LAIV [17,20,21]. As noted 
above, LAIV was in use during the seasons our study was conducted 2014–15 and 2015–
16). Subsequently, the ACIP recommended that LAIV should not be used in the U.S. during 
2016–17 and 2017–18 influenza seasons, due to concerns about its effectiveness [1,22]. 
However, LAIV continues to be recommended and used in some other countries such as 
Canada and United Kingdom [23,24]. We saw no difference in wheezing/chest tightness by 
vaccine type in children with a recent asthma/RAD/recurrent wheeze history, but very few of 
those children received LAIV since there was a precaution against the use of LAIV in 
children with asthma or recurrent wheezing. Other studies have shown that IIV does not 
significantly increase asthma exacerbations immediately after vaccination in children over 
three years of age [25,26], and our proportion of wheezing/chest tightness episodes were 
similar to published data [25]. In our study, the majority of parent-reported wheezing and/or 
chest tightness episodes did not result in medically-attended visits, highlighting the 
importance of methods to collect data directly from participants as a complement to EHR 
monitoring. While these events may be considered as medically less serious since they do 
not require medical care, they may affect parental perceptions of vaccine safety [27–31]. 
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Being able to assess a fuller complement of both medically-attended and non-medically-
attended adverse events would be advantageous when evaluating a new vaccine.
While there could have been a potential concern that having parents directly report vaccine 
safety data may make them feel less safe about a vaccine, we found the opposite was true. 
This is similar to our findings in pregnant women for whom taking part in text message 
monitoring led to a perceived increase in positive views about vaccine safety [32]. Two 
potential reasons for this positive effect are that, first, parents are more aware that vaccines 
are carefully monitored [33,34], and, second, that as parents pay more attention in the post-
vaccination period they realize their child did not experience any health issues.
A number of lessons were also learned about using text messaging for vaccine adverse event 
monitoring. First, while response rates drop off when texting daily for a number of days in a 
row, as seen in our previous studies [4,5], sending messages weekly for up to 6 weeks 
appears to be well-tolerated with sustained response rates. Second, it is helpful to build into 
the text messaging error messages that ask for clarification to cut down on erroneous 
responses, as well as to have unanswered text messages re-sent after 20 minutes to help 
prompt a response. For example, in response to the first message of the temperature cascade 
sent on day 0, an automated message was triggered 6.4% of the time to clarify a response; 
88.2% resulted in correction of the initial response. In addition, a repeat message was 
triggered 27.1% of the time due to lack of response; 91.7% responded with data. Finally, 
specific to screening for asthma, we found that parent report of asthma medication use 
within the last 12 months was a fairly accurate indicator (>90%) of a chart-adjudicated 
recent asthma/RAD/recurrent wheeze history, which may be helpful for future studies.
This observational study had a number of limitations. While there was potential for 
underreporting, most episodes of wheezing and/or chest tightness were reported via text 
message. We could not reach all parents by phone to confirm symptoms in year one, and 
respiratory symptoms were confirmed by phone but not by medical exam. However, if a 
system such as this were used in a pandemic most episodes would also not be verified by a 
provider examination. There is previous evidence that caregiver report of lower respiratory 
symptoms in young children is sensitive, particularly when reporting wheeze [35]. Of note, 
if text messaging were to be used in a large scale post-licensure study, a text message report 
could be used to trigger a study visit, if desired. An additional limitation is that limiting the 
denominator by data reporting levels may have increased fever and wheezing rates, but 
overall rates were low. Finally, while the study being conducted at two geographically 
distant and demographically distinct sites is a strength, it may not be generalizable to other 
locations.
5. Conclusion
This study demonstrates the feasibility and acceptability of using text messaging to assess 
pediatric respiratory symptoms after influenza vaccination through 6 weeks post-
vaccination. The results also illustrate the capacity to monitor post-vaccination fever and 
wheezing across more than one site, which could be helpful during an influenza pandemic or 
other emergency vaccination program.
Stockwell et al. Page 8
Vaccine. Author manuscript; available in PMC 2019 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
We would like to thank Theresa Harrington MD MPH TM and Oidda Museru RN, MSN, MPH from the Centers for 
Disease Control and Prevention (CDC) for their technical contributions to the study, New York-Presbyterian 
Hospital for its support of the EzVac Immunization Information System, and the New York-Presbyterian Hospital 
Ambulatory Care Network and its staff and patients. We would like to thank Luis Alba, Zuleika Parra Valencia, 
Ormarys Castellanos, and Ameriangel Roman from Columbia University and Mary Banks from Boston Medical 
Center for their help in this study.
M.S. Stockwell is a co-investigator but receives no financial support for an unrelated, investigator-initiated grant 
from the Pfizer Medical Education Group. The other authors have no conflicts of interests or financial disclosures.
Source of funding
This study was supported through the Clinical Immunization Safety Assessment (CISA) Project Contract No. 
200-2012-53665-0004 from the Centers for Disease for Control and Prevention (CDC).
References
[1]. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with 
vaccines: recommendations of the Advisory Committee on Immunization Practices - United 
States, 2017–18 influenza season. MMWR Recomm Rep 2017;66(2):1–20.
[2]. Gerdil C The annual production cycle for influenza vaccine. Vaccine 2003;21(16):1776–9. 
[PubMed: 12686093] 
[3]. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM. Signal identification and evaluation for risk of 
febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety 
Datalink Project, 2010–2011. Vaccine 2012;30(11):2024–31. [PubMed: 22361304] 
[4]. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated 
influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr 2014;168(3):
211–9. [PubMed: 24395025] 
[5]. Stockwell MS, Broder KR, Lewis P, et al. Assessing fever frequency after pediatric live attenuated 
versus inactivated influenza vaccination. J Pediatric Infect Dis Soc. 2016.
[6]. Pillsbury A, Cashman P, Leeb A, et al. Real-time safety surveillance of seasonal influenza vaccines 
in children, Australia, 2015. Euro Surveill 2015;20(43).
[7]. Westphal DW, Williams SA, Leeb A, Effler PV. Continuous active surveillance of adverse events 
following immunisation using SMS technology. Vaccine 2016;34(29):3350–5. [PubMed: 
27206385] 
[8]. U.S. Department of Health and Human Services. Using health text messages to improve consumer 
health knowledge, behaviors, and outcomes: an environmental scan. Rockville (MD): U.S. 
Department of Health and Human Services; 2014.
[9]. Mobile Fact Sheet, Pew Research Center; 2017 Available at <http://www.pewinternet.org/fact-
sheet/mobile/> [accessed on April 14, 2017].
[10]. Blumberg SJ, Luke JV. Reevaluating the need for concern regarding noncoverage bias in landline 
surveys. Am J Public Health 2009;99(10):1806–10. [PubMed: 19696381] 
[11]. Moro PL, Li R, Haber P, Weintraub E, Cano M. Surveillance systems and methods for 
monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and 
Prevention. Expert Opin Drug Saf 2016;15(9):1175–83. [PubMed: 27268157] 
[12]. SmartVax. Available at <http://www.smartvax.com.au> [accessed on September 27, 2017].
[13]. Centers for Disease Control and Prevention. Institute of Medicine Reports on Vaccine Safety. 
Available at <http://www.cdc.gov/vaccinesafety/research/iomreports/index.html> [accessed on 
April 14, 2017].
Stockwell et al. Page 9
Vaccine. Author manuscript; available in PMC 2019 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[14]. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with 
vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - 
United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 2014;63(32):691–7. 
[PubMed: 25121712] 
[15]. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and 
control of influenza with vaccines: recommendations of the Advisory Committee on 
Immunization Practices, United States, 2015–16 influenza season. MMWR Morb Mortal Wkly 
Rep 2015;64(30):818–25. [PubMed: 26247435] 
[16]. Greenes DS, Fleisher GR. Accuracy of a noninvasive temporal artery thermometer for use in 
infants. Arch Pediatr Adolesc Med 2001;155(3):376–81. [PubMed: 11231805] 
[17]. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine 
in infants and young children. N Engl J Med 2007;356(7):685–96. [PubMed: 17301299] 
[18]. Rowhani-Rahbar A, Klein NP, Dekker CL, et al. Biologically plausible and evidence-based risk 
intervals in immunization safety research. Vaccine 2012;31(1):271–7. [PubMed: 22835735] 
[19]. Marangu D, Kovacs S, Walson J, et al. Wheeze as an adverse event in pediatric vaccine and drug 
randomized controlled trials: a systematic review. Vaccine 2015;33(41):5333–41. [PubMed: 
26319071] 
[20]. Ambrose CS, Dubovsky F, Yi T, Belshe RB, Ashkenazi S. The safety and efficacy of live 
attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin 
Microbiol Infect Dis 2012;31(10):2549–57. [PubMed: 22410646] 
[21]. Tennis P, Toback SL, Andrews EB, McQuay LJ, Ambrose CS. A US postmarketing evaluation of 
the frequency and safety of live attenuated influenza vaccine use in nonrecommended children 
younger than 5years: 2009–2010 season. Vaccine 2012;30(42):6099–102. [PubMed: 22841479] 
[22]. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with 
vaccines. MMWR Recomm Rep 2016;65(5):1–54.
[23]. Flu Plan Winter; 2017. Available at <https://www.gov.uk/government/uploads/system/uploads/
attachment_data/file/600532/annual_flu_plan_2017to2018.pdf> [accessed on October 11. 2017].
[24]. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza 
Vaccine for 2017–2018. Available at <https://www.canada.ca/en/public-health/services/
publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-
vaccine-2017-2018.html> [accessed on October 11, 2017].
[25]. Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane 
Database Syst Rev 2013(2):CD000364.
[26]. Quach C Vaccinating high-risk children with the intranasal live-attenuated influenza vaccine: the 
Quebec experience. Paediatr Respir Rev 2014;15(4):340–7. [PubMed: 25242731] 
[27]. Freed GL, Clark SJ, Butchart AT, Singer DC, Davis MM. Parental vaccine safety concerns in 
2009. Pediatrics 2010;125(4):654–9. [PubMed: 20194286] 
[28]. Nyhan B, Reifler J. Does correcting myths about the flu vaccine work? An experimental 
evaluation of the effects of corrective information. Vaccine 2015;33(3):459–64. [PubMed: 
25499651] 
[29]. Grant VJ, Le Saux N, Plint AC, et al. Factors influencing childhood influenza immunization. 
CMAJ 2003;168(1):39–41. [PubMed: 12515783] 
[30]. Healy CM, Montesinos DP, Middleman AB. Parent and provider perspectives on immunization: 
are providers overestimating parental concerns? Vaccine 2014;32(5):579–84. [PubMed: 
24315883] 
[31]. Stockwell MS, Irigoyen M, Andres Martinez R, Findley SE. Failure to return: parental, practice, 
and social factors affecting missed immunization visits for urban children. Clin Pediatr (Phila) 
2014;53(5):420–7. [PubMed: 24647698] 
[32]. Stockwell MS, Cano M, Jakob K, et al. Feasibility of text message influenza vaccine safety 
monitoring during pregnancy. Am J Prev Med 2017.
[33]. Byington CL. Vaccines: can transparency increase confidence and reduce hesitancy? Pediatrics 
2014;134(2):377–9. [PubMed: 25086161] 
[34]. Dube E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. 
Hum Vaccin Immunother 2013;9(8):1763–73. [PubMed: 23584253] 
Stockwell et al. Page 10
Vaccine. Author manuscript; available in PMC 2019 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[35]. Samet JM, Cushing AH, Lambert WE, et al. Comparability of parent reports of respiratory 
illnesses with clinical diagnoses in infants. Am Rev Respir Dis 1993;148(2):441–6. [PubMed: 
8342910] 
Stockwell et al. Page 11
Vaccine. Author manuscript; available in PMC 2019 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 1. Study enrollment flow.
*Two participants removed by investigators after enrollment
• One child traveled outside U.S. on day 3 and parent did not have text messaging service 
out of the country
• One parent reported on sibling of enrolled child. The sibling was too young to be eligible 
for the study.
LATV4: Quadrivalent Live Attenuated Influenza Vaccine, IIV4: Quadrivalent Inactivated 
Influenza Vaccine
CUMC: Columbia University Medical Center; BMC: Boston Medical Center
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Fig.2. Response rates to text messages day 0 (day of vaccination) to day 42.
Site 1: Columbia University Medical Center
Site 2: Falls River (Boston Medical Center)
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Fig. 3. Primary data source for (A) temperature data and (B) respiratory symptom data in study 
year 1 (Y1) and year 2 (Y2).
Primary data source categorized as text if had text information available, diary if no text 
information was available, phone if no text or diary information was available. Diary was 
available only for days 3 and 7.
Site 1 : Columbia University Medical Center, Site 2: Falls River (Boston Medical Center)
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Table 1
Characteristics of study population.
Year 1 Year 2 Study total
(n = 166) (n = 100) (n = 266)
Sex
Male 95 (57.2%) 55 (55.0%) 150 (56.4%)
Female 71 (42.8%) 45 (45.0%) 116(43.6%)
Age
2 to <5 years 75 (45.2%) 28 (28.0%) 103 (38.7%)
5 to <8 years 47 (28.3%) 25 (25.0%) 72 (27.1%)
8 to <12 years 44 (26.5%) 47 (47.0%) 91 (34.2%)
Latino 101 (60.8%) 14 (14.0%) 115 (43.2%)
Race
Black/African American 27 (16.3%) 6 (6.0%) 33 (12.4%)
White 70 (42.2%) 84 (84.0%) 154 (57.9%)
Asian 1 (0.6%) 1 (1.0%) 2 (0.8%)
Native American 4 (2.4%) 1 (1.0%) 5 (1.9%)
Multiracial 40 (24.1%) 7 (7.0%) 47 (17.7%)
Other 24 (14.5%) 1 (1.0%) 25 (9.4%)
Asthma history overalla 62 (37.3%) 69 (69.0%) 131 (49.2%)
History ≤12 months 48 (28.9%) 64 (64.0%) 112 (42.1%)
History >12 months 14 (8.4%) 5 (5.0%) 19 (7.1%)
Language caregiver most comfortable
English 108 (65.1%) 100 (100%) 208 (78.2%)
Spanish 58 (34.9%) 0 (0%) 58 (21.8%)
Insurance
Commercial 24 (14.5%) 39 (39.0%) 63 (23.7%)
Public 141 (84.9%) 60 (60.0%) 201 (75.6%)
Uninsured 1 (0.6%) 1 (1.0%) 2 (0.8%)
Unlimited text message plan 153 (93.9%) 98 (98.0%) 251 (95.4%)
Receive text messages daily 158 (95.8%) 100 (100%) 258 (97.4%)
Vaccine type
LAIV4 54 (32.5%) 18 (18.0%) 72 (27.1%)
IIV4 112 (67.5%) 82 (82.0%) 194 (72.9%)
LAIV4
LAIV4 alone 41 (75.9%) 12 (66.7%) 53 (73.6%)
LAIV4 with other vaccines 13 (24.1%) 6 (33.3%) 19 (26.4%)
IIV4
IIV4 alone 87 (77.7%) 62 (75.6%) 149 (76.8%)
IIV4 with other vaccines 25 (22.3%) 20 (24.4%) 45 (23.2%)
Year 1 2014–2015 (two sites), Year 2 2015–2016 (one site).
Vaccine. Author manuscript; available in PMC 2019 August 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Stockwell et al. Page 16
LAIV4: Quadrivalent Live Attenuated Influenza Vaccine, IIV4: Quadrivalent Inactivated Influenza Vaccine.
aAsthma history <12 months includes documentation of asthma exacerbation and/or asthma medication prescription documented within 12 months 
before enrollment (i.e., recent history). Asthma history >12 months indicates has an asthma/RAD/ recurrent wheezing diagnosis but does not meet 
criteria as above (i.e., remote history).
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